AKT1/PKBα Kinase Is Frequently Elevated in Human Cancers and Its Constitutive Activation Is Required for Oncogenic Transformation in NIH3T3 Cells-Reference-Cited by-同舟云学术

AKT1/PKBα Kinase Is Frequently Elevated in Human Cancers and Its Constitutive Activation Is Required for Oncogenic Transformation in NIH3T3 Cells

Published:2001-08 Issue:2 Volume:159 Page:431-437
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Sun Mei,Wang Gen,Paciga June E.,Feldman Richard I.,Yuan Zeng-Qiang,Ma Xiao-Ling,Shelley Sue A.,Jove Richard,Tsichlis Philip N.,Nicosia Santo V.,Cheng Jin Q.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference38 articles.

1. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region;Bellacosa;Science,1991

2. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas;Cheng;Proc Natl Acad Sci USA,1992

3. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily;Jones;Proc Natl Acad Sci USA,1991

4. Molecular cloning of a second form of rac protein kinase;Jones;Cell Regul,1991

5. Identification of a human AKT3 (protein kinase Bγ) which contains the regulatory serine phosphorylation site;Nakatani;Biochem Biophys Res Comm,1999

Cited by 392 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Mutations in AKT1 Gene in Prostate Cancer Patients in Jordan;Current Issues in Molecular Biology;2024-09-04

2. Identification of prostate cancer associated genes for diagnosis and prognosis: a modernized in silico approach;Mammalian Genome;2024-08-17

3. The oncogenic fusion protein EML4-NTRK3 requires three salt bridges for stability and biological activity;Heliyon;2024-08

4. Critical domains for NACC2-NTRK2 fusion protein activation;PLOS ONE;2024-06-27

5. miR-192 family in breast cancer: Regulatory mechanisms and diagnostic value;Biomedicine & Pharmacotherapy;2024-06